3 Urea and Crop Nutrients Company, Global IT Services Provider and National Diagnostics Network Stocks With a Strong Future Roadmap: Chambal Fertilisers and Chemicals, Coforge and Dr. Lal PathLabs
- November 4, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Chambal Fertilisers and Chemicals, Coforge and Dr. Lal PathLabs: ROE of 16.3% to 20.1% and FY22 to FY26 revenue CAGR of 6.7% to 26.3%. Prices as of 3 Nov 2026.
Quick Answer
The three urea, IT services and pathology stocks to watch are Chambal Fertilisers and Chemicals, Coforge and Dr. Lal PathLabs. Their return on equity ranges from 16.3% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.7% to 26.3%. Dr. Lal PathLabs has the highest return on equity at 20.1%, while Coforge has the fastest revenue growth at 26.3% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Urea, IT services and pathology stocks bring together companies with a visible plan for the years ahead. Chambal Fertilisers and Chemicals, Coforge and Dr. Lal PathLabs cover a urea and crop nutrients company, a global IT services provider and a national diagnostics network.
This list covers three urea, IT services and pathology stocks with complete current figures: Chambal Fertilisers and Chemicals, Coforge and Dr. Lal PathLabs. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Urea, IT Services and Pathology Stocks?
Urea, IT services and pathology stocks are listed companies that make urea and trade fertilisers and agri inputs, deliver cloud, data and engineering services to global clients, and run a national network of laboratories and patient service centres. Their earnings depend on farm demand, client technology budgets and test volumes.
Urea, IT Services and Pathology Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Chambal Fertilisers and Chemicals | 381.7 | 15,339 | 8.0 | 21.2 | 18.8 | 0.10 |
| Coforge | 2,060.8 | 85,024 | 44.3 | 17.5 | 16.3 | 0.08 |
| Dr. Lal PathLabs | 1,925.7 | 30,949 | 56.6 | 59.6 | 20.1 | 0.08 |
On valuation, Chambal Fertilisers and Chemicals and Dr. Lal PathLabs trade at a P/E below the industry P/E, while Coforge trades above it, which reflects the growth the market already expects. Readers comparing urea, IT services and pathology stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in urea, IT services and pathology stocks can use the coming numbers to test whether growth is holding.
Why Do Urea, IT Services and Pathology Stocks Have a Strong Roadmap in India?
Urea, IT services and pathology stocks have a strong roadmap in India because steady farm activity, rising digital engineering demand and growing health awareness keep widening the market for these companies.
- Urea and nutrients. Farms need steady fertiliser supply.
- IT services. Travel and insurance clients modernise systems.
- Diagnostics. More people take regular tests.
Why Chambal Fertilisers and Chemicals Features Among These Urea, IT Services and Pathology Stocks
Among the urea, IT services and pathology stocks on this list, Chambal Fertilisers and Chemicals makes urea at its plants in Rajasthan and trades in other fertilisers, crop protection chemicals and agri inputs.
The company has a return on equity of 18.8%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 15,339 crore. The stock trades at a P/E of 8.0, below the industry P/E of 21.2.
Revenue rose from Rs 16,137 crore in FY22 to Rs 20,921 crore in FY26, a compound annual growth rate of 6.7%. Net profit grew from Rs 1,566 crore in FY22 to Rs 1,953 crore in FY26, which works out to a compound annual growth rate of 5.7%.
Roadmap: The company has a strong urea franchise with large volumes and a wide dealer network. It is widening into crop protection and specialty agri inputs, which adds higher-margin revenue to the base fertiliser business.
What to watch: Track fertiliser subsidy policy updates and the monsoon, which both influence volumes and working capital.
Why Coforge Features Among These Urea, IT Services and Pathology Stocks
Among the farm input and services shares on this list, Coforge is a global IT services company that offers digital engineering, cloud, data and application services to clients in travel, banking, insurance and other industries.
Revenue rose from Rs 6,484 crore in FY22 to Rs 16,476 crore in FY26, a compound annual growth rate of 26.3%. Net profit grew from Rs 715 crore in FY22 to Rs 1,674 crore in FY26, which works out to a compound annual growth rate of 23.7%.
In the June 2026 quarter, revenue grew 49.2% year on year to Rs 5,554 crore, while net profit rose 49.2% to Rs 532 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 85,024 crore. The stock trades at a P/E of 44.3, above the industry P/E of 17.5.
Roadmap: The company focuses on large, long-running deals in sectors where it has deep domain strength. A rising share of cloud and data work and the acquisition of a leading digital services business have strengthened its pipeline.
What to watch: Check the order intake and the pace of large deal conversion.
Why Dr. Lal PathLabs Features Among These Urea, IT Services and Pathology Stocks
Among the three companies on this list, Dr. Lal PathLabs is one of India’s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.
In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%.
Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6.
Roadmap: Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
What to watch: Follow test volumes per patient and the balance between routine and specialised tests.
Chambal Fertilisers and Chemicals vs Coforge vs Dr. Lal PathLabs on Key Financials
The table below sets the three urea, IT services and pathology stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Chambal Fertilisers and Chemicals | 16,137 | 20,921 | 6.7% | 1,953 | 9.3% |
| Coforge | 6,484 | 16,476 | 26.3% | 1,674 | 10.2% |
| Dr. Lal PathLabs | 2,140 | 2,864 | 7.6% | 510 | 17.8% |
Dr. Lal PathLabs posts the highest return on equity in this group at 20.1%. Chambal Fertilisers and Chemicals has the largest FY26 revenue at Rs 20,921 crore, and Coforge shows the fastest revenue growth with a 26.3% compound annual rate. A useful habit with urea, IT services and pathology stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Urea, IT Services and Pathology Stocks
Every theme carries risks that deserve a check before any decision. For these urea, IT services and pathology stocks, the main points are: Long-term farm input and services shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Farm cycles. Tractor and crop input demand follows the monsoon and farm incomes.
- Client spending. Technology budgets can vary with global conditions.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter urea, IT services and pathology stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Urea, IT Services and Pathology Stocks
Urea, IT services and pathology stocks suit investors who prefer to study business strength before price moves. Chambal Fertilisers and Chemicals, Coforge and Dr. Lal PathLabs each have a clear plan to grow. Based on the 3 November 2026 close, Chambal Fertilisers and Chemicals trades at Rs 381.7, Coforge at Rs 2,060.8 and Dr. Lal PathLabs at Rs 1,925.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these urea, IT services and pathology stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track urea, IT services and pathology stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are urea, IT services and pathology stocks?
Ans. Urea, IT services and pathology stocks are listed companies that make urea and trade fertilisers and agri inputs, deliver cloud, data and engineering services to global clients, and run a national network of laboratories and patient service centres. Their earnings depend on farm demand, client technology budgets and test volumes. This list looks at three of them, Chambal Fertilisers and Chemicals, Coforge and Dr. Lal PathLabs, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which urea, IT services and pathology stocks are covered in this list?
Ans. This list covers Chambal Fertilisers and Chemicals, Coforge and Dr. Lal PathLabs. Based on the 3 November 2026 close, Chambal Fertilisers and Chemicals traded at Rs 381.7, Coforge at Rs 2,060.8 and Dr. Lal PathLabs at Rs 1,925.7. Their return on equity ranges from 16.3% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.7% to 26.3%.
Why do urea, IT services and pathology stocks have a strong future roadmap in India?
Ans. Urea, IT services and pathology stocks have a strong roadmap in India because steady farm activity, rising digital engineering demand and growing health awareness keep widening the market for these companies. The main drivers are as follows. Urea and nutrients. Farms need steady fertiliser supply. IT services. Travel and insurance clients modernise systems. Diagnostics. More people take regular tests. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Chambal Fertilisers and Chemicals performed financially?
Ans. Revenue rose from Rs 16,137 crore in FY22 to Rs 20,921 crore in FY26, a compound annual growth rate of 6.7%. Net profit grew from Rs 1,566 crore in FY22 to Rs 1,953 crore in FY26, which works out to a compound annual growth rate of 5.7%. The company has a return on equity of 18.8%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 15,339 crore. The stock trades at a P/E of 8.0, below the industry P/E of 21.2. Looking ahead, the company has a strong urea franchise with large volumes and a wide dealer network. It is widening into crop protection and specialty agri inputs, which adds higher-margin revenue to the base fertiliser business.
How has Coforge performed financially?
Ans. Revenue rose from Rs 6,484 crore in FY22 to Rs 16,476 crore in FY26, a compound annual growth rate of 26.3%. Net profit grew from Rs 715 crore in FY22 to Rs 1,674 crore in FY26, which works out to a compound annual growth rate of 23.7%. In the June 2026 quarter, revenue grew 49.2% year on year to Rs 5,554 crore, while net profit rose 49.2% to Rs 532 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 85,024 crore. The stock trades at a P/E of 44.3, above the industry P/E of 17.5. Looking ahead, the company focuses on large, long-running deals in sectors where it has deep domain strength. A rising share of cloud and data work and the acquisition of a leading digital services business have strengthened its pipeline.
How has Dr. Lal PathLabs performed financially?
Ans. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
What risks should investors check before buying urea, IT services and pathology stocks?
Ans. Investors should check a few risks before buying urea, IT services and pathology stocks. Farm cycles. Tractor and crop input demand follows the monsoon and farm incomes. Client spending. Technology budgets can vary with global conditions. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of urea, IT services and pathology stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
